Investigational drug · Phase 3
BAT1308
Also called: Recombinant humanized anti-PD-1 monoclonal antibody
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Cervical Cancer, Advanced Solid Tumors.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
7
Any phase or sponsor naming "BAT1308"
First trial start
2023
Dec 13, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BAT1308", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cervical Cancer
- Advanced Solid Tumors
Approved drugs for the same conditions: Cervical cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "BAT1308" as an intervention, largest first.
- BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical CancerPivotal-lookingRecruiting
Bio-Thera SolutionsIndustry
NCT06123884 · 526 participants (planned) · Start Dec 13, 2023 · Primary completion Sep 2026
Drug: Recombinant humanized anti-PD-1 monoclonal antibody injection; Cisplatin and 3 more · For: Cervical Cancer
Sites: Wuhan, China
- A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid TumorsActive, not recruiting
Bio-Thera SolutionsIndustry
NCT06341114 · 112 participants (planned) · Start Apr 12, 2024 · Primary completion Nov 30, 2026
Drug: BAT8008 injection; BAT1308 injection · For: Advanced Solid Tumors
Sites: Hangzhou, China
Bio-Thera SolutionsIndustry
NCT05155722 · 59 participants · Start Sep 17, 2020 · Primary completion Jul 9, 2024
Drug: BAT1308 · For: Advanced Solid Tumor
Sites: Zhengzhou, China
Bio-Thera SolutionsIndustry
NCT06139536 · 35 participants · Start Mar 6, 2024 · Primary completion Dec 2, 2025
Drug: BAT4706 Injection; BAT1308 Injection · For: Advanced Solid Tumor
Sites: Zhengzhou, China; Linyi, China · 3 sites in all
Bio-Thera SolutionsIndustry
NCT05073484 · 13 participants · Start Oct 29, 2021 · Primary completion Mar 30, 2023
Drug: BAT6021; BAT1308 · For: Advanced Solid Tumor
Sites: Liverpool, Australia; Sydney, Australia; Melbourne, Australia
Bio-Thera SolutionsIndustry
NCT05109650 · 13 participants · Start Feb 28, 2022 · Primary completion Mar 23, 2023
Drug: BAT6026; BAT1308 · For: Advanced Solid Tumour
Sites: Kogarah, Australia; Sydney, Australia · 3 sites in all
- BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial CancerPivotal-lookingTerminated
Bio-Thera SolutionsIndustry
NCT06321068 · 5 participants · Start Apr 9, 2024 · Primary completion May 30, 2025
Drug: carboplatin; Paclitaxel and 1 more · For: Endometrial Cancer
Sites: Chongqing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Cervical Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- CadonilimabAK104Phase 331 trials
Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- ZimberelimabAB122, GS-0122Phase 312 trials
Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer
- 9MW2821Phase 311 trials
Mabwell (Shanghai) Bioscience Co., Ltd. · Urothelial Carcinoma, Advanced Urothelial Carcinoma, Locally Advanced or Metastatic Triple-negative Breast Cancer
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- SYS6002Phase 35 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Urothelial Carcinoma, Cervical Cancer, Advanced Solid Tumors
- JSKN033Phase 34 trials
Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Cervical Cancer, Recurrent or Metastatic Cervical Cancer, Advanced Malignant Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.